Fulcrum Therapeutics Stock Price, News & Analysis

Fulcrum Therapeutics (FULC) will release its Q3 2021 financial results on November 4, 2021, before U.S. markets open. A conference call and webcast will follow at 8:00 a.m. ET to discuss results and recent corporate developments. Fulcrum's focus is on patients with genetically defined rare diseases, with notable advancements including losmapimod in Phase 2 trials for facioscapulohumeral muscular dystrophy and FTX-6058 in Phase 1 trials for sickle cell disease and beta-thalassemia.

Fulcrum Therapeutics (Nasdaq: FULC) announced the approval of an inducement award for Naomi Aoki, the newly appointed SVP of Communications and Investor Relations, on September 10, 2021. The grant includes a nonstatutory stock option for 58,000 shares at an exercise price of $28.21, the closing price on September 30, 2021. The option has a ten-year term and vests over four years, promoting retention through gradual vesting. Fulcrum Therapeutics focuses on developing treatments for genetically defined rare diseases, advancing losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease.

Fulcrum Therapeutics (FULC) has announced the presentation of multiple posters and oral presentations on losmapimod for facioscapulohumeral muscular dystrophy (FSHD) at the Virtual Congress of the World Muscle Society. Results from the Phase 2b ReDUX4 trial indicate significant benefits across various clinical endpoints. The company plans to meet with regulators in Q4 2021 and provide updates on losmapimod's clinical path in Q1 2022. FSHD currently has no approved therapies, highlighting the importance of this research.

Fulcrum Therapeutics (Nasdaq: FULC) announced the grant of a nonstatutory stock option to Mel Hayes, its newly appointed Chief Commercial Officer, as part of an inducement award. The award includes an option to purchase up to 140,000 shares at an exercise price of $28.49. This grant, approved on August 4, 2021, is valid for ten years and vests over four years. Fulcrum focuses on patients with rare genetically defined diseases, advancing treatments like losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease.

Fulcrum Therapeutics (Nasdaq: FULC) has appointed Mel Hayes as Chief Commercial Officer, effective September 7, 2021. Hayes, an industry veteran with over 25 years of experience in product commercialization, will lead the company's global strategy to maximize the potential of its therapies. The company is transitioning to a commercial-stage organization following advancements in its product pipeline, including losmapimod and FTX-6058, aimed at treating rare genetic diseases.

Fulcrum Therapeutics, a clinical-stage biopharmaceutical company focused on genetically defined rare diseases, announced its participation in key investor conferences. Management will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 4:15 p.m. ET, followed by the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. ET, and the Cantor Virtual Global Healthcare Conference on September 28, 2021, at 3:20 p.m. ET. Live audio webcasts will be accessible on Fulcrum's Investor Relations page.

Fulcrum Therapeutics, Inc. (Nasdaq: FULC) announced the closing of its public offering of 7,590,000 shares at $19.00 each, raising $144.2 million in gross proceeds. The offering included 990,000 shares purchased at the underwriters' exercise option. The shares were sold under a previously effective SEC registration statement. SVB Leerink, Piper Sandler & Co., and Stifel served as joint bookrunning managers, while H.C. Wainwright & Co. led the offering management. The funds will support Fulcrum's ongoing clinical development of therapeutics for genetically defined rare diseases.

Fulcrum Therapeutics, Inc. (Nasdaq: FULC) has announced the pricing of a public offering of 6,600,000 shares of its common stock at $19.00 per share, aiming for total gross proceeds of approximately $125 million before expenses. The offering is expected to close on August 16, 2021. Additionally, underwriters have a 30-day option to purchase up to 990,000 extra shares. The offering is being conducted under a shelf registration statement and involves joint bookrunning managers SVB Leerink, Piper Sandler & Co., and Stifel.

Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, has announced a public offering of $100 million in common stock, with an option for underwriters to purchase an additional $15 million. The offering is managed by SVB Leerink, Piper Sandler & Co., and Stifel. Fulcrum plans to use the proceeds to advance its clinical development programs, including drugs for rare diseases. The offering is subject to market conditions and follows a previously filed shelf registration with the SEC.